Celebrex Has Lower Risk Of Death Than Vioxx Or NSAIDs In CHF Patients, Study Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The study in the British Medical Journal finds risk of death and recurrent congestive heart failure higher in patients on Vioxx or NSAIDs than Celebrex. A second study in the same issue finds "significantly increased" risk of myocardial infarction in patients using Vioxx, diclofenac or ibuprofen, but not Celebrex or naproxen.
You may also be interested in...
Silver Lining For Pfizer? Celebrex Well-Positioned In NSAID Class
The boxed warning for Pfizer's Celebrex will differ only slightly from labeling for other prescription NSAIDs, FDA says. All products will bear new language addressing increased cardiovascular and gastrointestinal risks. The agency appears open to renewed direct-to-consumer advertising for Celebrex.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.